Startups
We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
Overview
Location
United States, Texas, Austin
Employees
11-50
Phone
+1 877-774-4679
Total raised
$10M
Founded date
2009
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 4, 2024 | Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes | Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes AUSTIN, Texas, Sept. 4, 2024 /PRNewswire/ -- Genprex, Inc. (&q... |
| May 14, 2024 | Clinical Trials Commenced for Immunogene Therapy: Advancing Small Cell Lung Cancer Treatment : Genprex; NASDAQ: GNPX | Genprex, Inc. NASDAQ: GNPX Genprex, Inc. NASDAQ: GNPX Cancer Gene Therapy: NASDAQ: GNPX Genprex NASDAQ: Stock Symbol: GNPX GNPX in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer. Genent... |
| May 13, 2024 | Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors | Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-s... |
| May 13, 2024 | New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms :NASDAQ: GNPX | Genprex, Inc. NASDAQ: GNPX Genprex, Inc. NASDAQ: GNPX Cancer Gene Therapy: NASDAQ: GNPX Genprex NASDAQ: Stock Symbol: GNPX Genprex, Inc. Names New Leadership Following Breakthrough Preclinical Results in Cancer Gene Therapy: Genprex, Inc. (... |
| May 1, 2024 | Genprex to Present and Participate at Upcoming May Investor and Industry Conferences | AUSTIN, Texas, May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diab... |
| Mar 14, 2023 | Genprex's Diabetes Gene Therapy Program: A Major Step Forward in the Fight Against Type 1 Diabetes | Noah Miller, Tech Times 14 March 2023, 11:03 am (Photo : Genprex) Type 1 diabetes is a chronic autoimmune disease affecting millions of people globally, characterized by the destruction of insulin-producing beta cells in the pancreas. Patie... |
| Feb 1, 2021 | GENPREX, INC. Genprex : January 2021 Shareholder Letter | GENPREX CORPORATE UPDATE January 2021 To my fellow shareholders: As we look back over the past year, we believe Genprex had a banner year, achieving important milestones that set the stage for a transformational 2021. I am especially proud ... |
| Feb 1, 2021 | Genprex : January 2021 Shareholder Letter | GENPREX CORPORATE UPDATE January 2021 To my fellow shareholders: As we look back over the past year, we believe Genprex had a banner year, achieving important milestones that set the stage for a transformational 2021. I am especially proud ... |
| May 9, 2018 | Term Sheet — Wednesday, May 9 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop It’s why she listened to Tinder’s Sean Rad when he told her he had a dating app idea. It’s why she constantly asks he... |
Show more
Reviews 0
FAQ about Genprex, Inc.
When was Genprex, Inc. founded?
Genprex, Inc. was founded in 2009.
How much funding has Genprex, Inc. raised?
Genprex, Inc. has raised $10M in total across 1 funding round.
What has the press written about Genprex, Inc.?
Parsers VC has collected 14 articles mentioning Genprex, Inc., among them “Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes” (Sep 4, 2024) and “Clinical Trials Commenced for Immunogene Therapy: Advancing Small Cell Lung Cancer Treatment : Genprex; NASDAQ: GNPX” (May 14, 2024).
Is Genprex, Inc. still active?
Yes, Genprex, Inc. is active; its latest activity on Parsers VC dates from Aug 3, 2026.